Placebo effects in treating migraine and other headaches

被引:0
作者
Diener, Hans-Christoph [1 ,2 ]
机构
[1] Univ Hosp Essen, Dept Neurol, D-45147 Essen, Germany
[2] Univ Hosp Essen, Headache Ctr, D-45147 Essen, Germany
关键词
TOXIN TYPE-A; RANDOMIZED CONTROLLED-TRIAL; RIZATRIPTAN; 5; MG; DOUBLE-BLIND; PROPHYLACTIC TREATMENT; DIVALPROEX SODIUM; PARALLEL-GROUP; TOPIRAMATE; EFFICACY; MULTICENTER;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Evaluating the efficacy of a drug therapy in the acute and prophylactic treatment of migraine requires the conduct of placebo-controlled, randomized clinical trials. In order to plan and conduct these studies in the most appropriate manner, it is desirable to know which factors influence the placebo response. This editorial overview discusses the factors that influence placebo response in trials for migraine and other headaches; such factors include expectation, blinding, route of drug administration, patient age and gender, and geographic distribution of the trials. The placebo response rates in the treatment of acute headache episodes are higher than in headache prophylaxis, and invasive procedures, such as injections, have a higher placebo response compared with orally administered drugs.
引用
收藏
页码:735 / 739
页数:5
相关论文
共 50 条
  • [31] The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments
    Korucu, O.
    Dagar, S.
    Corbacioglu, S. K.
    Emektar, E.
    Cevik, Y.
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 138 (03): : 212 - 218
  • [32] The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatments
    Evans, Kathryn
    Romero, Heather
    Spierings, Egilius L. H.
    Katz, Nathaniel
    CEPHALALGIA, 2021, 41 (02) : 247 - 255
  • [33] Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine
    Santos-Lasaosa, S.
    Cuadrado, M. L.
    Gago-Veiga, A. B.
    Guerrero-Peral, A. L.
    Irimia, P.
    Lainez, J. M.
    Leira, R.
    Pascual, J.
    Porta-Etessam, J.
    Sanchez del Rio, M.
    Viguera Romero, J.
    Pozo-Rosich, P.
    NEUROLOGIA, 2020, 35 (08): : 568 - 578
  • [34] Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies
    Evers, S.
    Marziniak, M.
    Frese, A.
    Gralow, I.
    CEPHALALGIA, 2009, 29 (04) : 436 - 444
  • [35] The effects of cinnarizine versus sodium valproate in migraine prophylaxis
    Bostani, Arash
    Rajabi, Aref
    Moradian, Nasrin
    Razazian, Nazanin
    Rezaei, Mansour
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2013, 123 (07) : 487 - 493
  • [36] The role of serotonin receptors in migraine headaches
    Sokolov, A. Y.
    Lyubashina, O. A.
    Panteleev, S. S.
    NEUROCHEMICAL JOURNAL, 2011, 5 (02) : 92 - 99
  • [37] A Comprehensive Review of Over-the-counter Treatment for Chronic Migraine Headaches
    Peck, Jacquelin
    Urits, Ivan
    Zeien, Justin
    Hoebee, Shelby
    Mousa, Mohammad
    Alattar, Hamed
    Kaye, Alan D.
    Viswanath, Omar
    CURRENT PAIN AND HEADACHE REPORTS, 2020, 24 (05)
  • [38] The use of migraine preventive medications among patients with and without migraine headaches
    Lafata, J. E.
    Tunceli, O.
    Cerghet, M.
    Sharma, K. P.
    Lipton, R. B.
    CEPHALALGIA, 2010, 30 (01) : 97 - 104
  • [39] A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine
    Winner, Paul K.
    Kabbouche, Marielle
    Yonker, Marcy
    Wangsadipura, Veronica
    Lum, Arlene
    Brin, Mitchell F.
    HEADACHE, 2020, 60 (03): : 564 - 575
  • [40] Homeopathic prophylaxis of headaches and migraine? A systematic review
    Ernst, E
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1999, 18 (05) : 353 - 357